Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Avagacestat in Prodromal Alzheimer's Disease
2009-010067-16Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Avagacestat with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started May 2009; status: completed.
02
Drugs
avagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-010067-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010067-16.